Biogen Inc

BIIBNASDAQ · USD
249.59USD0.00 (+1.00%)
6310

Biogen Inc (BIIB) Covered Calls

Biogen Inc trades in the Drug Manufacturers - General industry with an IV Rank of 100.00%, high versus the past year. BIIB's highest covered call setup is the $252.50 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 2.17% out of the money with 1 day to expiration, a 2.21% return until expiration, and a 807.89% theoretical annualized return. Across the setups shown, annualized returns run from 265.73% to 807.89% at strikes between $250.00 and $310.00, with 1 to 35 days to expiration, as of Nov 19, 2026.

Read more

Running BIIB covered calls helps you generate income from Biogen Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best BIIB covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If BIIB stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling BIIB covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given BIIB covered call is worth writing.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies.

2026-11-201252.502.170.103.90547.002.21807.89-0.04+0.31613.80
2026-11-201250.001.160.104.10297.001.20438.66-0.04+0.371724.00
2026-12-0415280.0013.300.053.403292.0013.32324.14-0.02+0.1423.35
2026-12-1829310.0025.440.103.506297.0025.48320.70-0.04+0.10383.40
2026-12-1829305.0023.420.453.605832.0023.60297.02-0.18+0.11253.15
2026-12-1122290.0017.350.154.204302.0017.41288.81-0.06+0.14104.05
2026-11-278262.506.220.053.501542.006.24284.68-0.02+0.20133.45
2026-12-0415275.0011.280.903.202877.0011.64283.28-0.36+0.1612.30
2026-12-1829300.0021.392.002.605487.0022.20279.45-0.81+0.131,1070.60
2026-12-2435310.0025.440.104.106297.0025.48265.73-0.04+0.1104.00

As of Nov 19, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryDrug Manufacturers - General
  • SectorHealthcare
  • IV Rank100.00% High
  • Market cap (M$)36,894
  • 52 weeks high-4.37%
  • 52 weeks low55.64%
  • Analyst recommendationBuy
    1.86
  • Target price$271.69
    8.85% above the current stock price
  • Dividend—
  • Payout ratio0.00%
  • Earnings date2027-02-05
  • P/E106.85
  • Future P/E15.40
  • EPS (ttm)2.34
  • EPS growth next 5 years6.41%

As of Nov 20, 2026